PLX
Price
$2.42
Change
-$0.19 (-7.31%)
Updated
Apr 4, 02:49 PM (EDT)
Capitalization
202.88M
35 days until earnings call
SNDX
Price
$11.24
Change
-$1.22 (-9.79%)
Updated
Apr 4, 04:36 PM (EDT)
Capitalization
1.07B
38 days until earnings call
Ad is loading...

PLX vs SNDX

Header iconPLX vs SNDX Comparison
Open Charts PLX vs SNDXBanner chart's image
Protalix BioTherapeutics
Price$2.42
Change-$0.19 (-7.31%)
Volume$100
Capitalization202.88M
Syndax Pharmaceuticals
Price$11.24
Change-$1.22 (-9.79%)
Volume$2.83K
Capitalization1.07B
PLX vs SNDX Comparison Chart
Loading...
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PLX vs. SNDX commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PLX is a Hold and SNDX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (PLX: $2.60 vs. SNDX: $12.46)
Brand notoriety: PLX and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PLX: 68% vs. SNDX: 54%
Market capitalization -- PLX: $202.88M vs. SNDX: $1.07B
PLX [@Biotechnology] is valued at $202.88M. SNDX’s [@Biotechnology] market capitalization is $1.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PLX’s FA Score shows that 1 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • PLX’s FA Score: 1 green, 4 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, PLX is a better buy in the long-term than SNDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PLX’s TA Score shows that 6 TA indicator(s) are bullish while SNDX’s TA Score has 4 bullish TA indicator(s).

  • PLX’s TA Score: 6 bullish, 4 bearish.
  • SNDX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, PLX is a better buy in the short-term than SNDX.

Price Growth

PLX (@Biotechnology) experienced а +0.78% price change this week, while SNDX (@Biotechnology) price change was -8.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.26%. For the same industry, the average monthly price growth was -17.11%, and the average quarterly price growth was -18.88%.

Reported Earning Dates

PLX is expected to report earnings on May 09, 2025.

SNDX is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-11.26% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNDX($1.07B) has a higher market cap than PLX($203M). PLX YTD gains are higher at: 38.298 vs. SNDX (-5.749). PLX has higher annual earnings (EBITDA): -6.48M vs. SNDX (-313.82M). SNDX has more cash in the bank: 583M vs. PLX (27.4M). PLX has less debt than SNDX: PLX (5.68M) vs SNDX (346M). PLX has higher revenues than SNDX: PLX (45.7M) vs SNDX (23.7M).
PLXSNDXPLX / SNDX
Capitalization203M1.07B19%
EBITDA-6.48M-313.82M2%
Gain YTD38.298-5.749-666%
P/E Ratio64.75N/A-
Revenue45.7M23.7M193%
Total Cash27.4M583M5%
Total Debt5.68M346M2%
FUNDAMENTALS RATINGS
PLX vs SNDX: Fundamental Ratings
PLX
SNDX
OUTLOOK RATING
1..100
8159
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
85
Overvalued
PROFIT vs RISK RATING
1..100
10094
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
3585
P/E GROWTH RATING
1..100
23
SEASONALITY SCORE
1..100
n/a37

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PLX's Valuation (80) in the Servicestothe Health Industry industry is in the same range as SNDX (85) in the Biotechnology industry. This means that PLX’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's Profit vs Risk Rating (94) in the Biotechnology industry is in the same range as PLX (100) in the Servicestothe Health Industry industry. This means that SNDX’s stock grew similarly to PLX’s over the last 12 months.

PLX's SMR Rating (96) in the Servicestothe Health Industry industry is in the same range as SNDX (98) in the Biotechnology industry. This means that PLX’s stock grew similarly to SNDX’s over the last 12 months.

PLX's Price Growth Rating (35) in the Servicestothe Health Industry industry is somewhat better than the same rating for SNDX (85) in the Biotechnology industry. This means that PLX’s stock grew somewhat faster than SNDX’s over the last 12 months.

PLX's P/E Growth Rating (2) in the Servicestothe Health Industry industry is in the same range as SNDX (3) in the Biotechnology industry. This means that PLX’s stock grew similarly to SNDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PLXSNDX
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 16 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
76%
View a ticker or compare two or three
Ad is loading...
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HGOIX59.35N/A
N/A
Hartford Growth Opportunities I
RYMMX55.68N/A
N/A
Rydex S&P MidCap 400 Pure Value C
FGFLX39.14N/A
N/A
Federated Hermes Intl Leaders IS
MPLAX13.47N/A
N/A
Praxis International Index A
LGCWX16.60N/A
N/A
Lord Abbett Global Equity R6

PLX and

Correlation & Price change

A.I.dvisor tells us that PLX and ZNTL have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PLX and ZNTL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PLX
1D Price
Change %
PLX100%
+0.39%
ZNTL - PLX
31%
Poorly correlated
-7.55%
CPRX - PLX
31%
Poorly correlated
-1.43%
SNDX - PLX
31%
Poorly correlated
-3.93%
LXRX - PLX
31%
Poorly correlated
-11.91%
MLTX - PLX
30%
Poorly correlated
+0.03%
More